WILLIAM ALVARADO: Open Payments
NPI 1831936582 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,493 in 277 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $1,725 · 2025 $4,493
Food & beverage: $4,493
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 39 | $757 |
| Neurocrine BioSciences, Inc. | 33 | $728 |
| Otsuka America Pharmaceutical, Inc. | 30 | $565 |
| Teva Pharmaceuticals USA, Inc. | 35 | $394 |
| Alkermes, Inc. | 21 | $363 |
| Lundbeck LLC | 25 | $331 |
| Vanda Pharmaceuticals Inc. | 11 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $232 |
| Axsome Therapeutics, Inc. | 10 | $195 |
| ABBVIE INC. | 18 | $177 |
Products named: CAPLYTA, REXULTI, INGREZZA, ARISTADA, TRINTELLIX, AUSTEDO XR, FANAPT, VRAYLAR.
Industry payments across NY — which companies pay providers there.
